BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company's Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company's Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company's Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company's subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.